NASDAQ$SERA
Sera Prognostics Inc-A · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Sera Prognostics' financial results for Q2 2024 were announced, showing a decrease in revenue but also a reduction in operating expenses and net loss.
Sera Prognostics reported a decrease in revenue for the second quarter of 2024, but also saw a reduction in operating expenses and a narrower net loss compared to the same period in the previous year.
- Second quarter revenue was $24,000, compared to $123,000 for the same period in 2023.
- Total operating expenses decreased by 20% to $9.3 million from $11.5 million in the second quarter of 2023.
- Net loss was $8.3 million, a 21% improvement compared to a net loss of $10.5 million for the same quarter a year ago.
- Research and development expenses increased by 19% to $4.4 million due to new product development activities.
Headline financials
Revenue & EPS history
Sera Prognostics · Revenue · Quarterly
$24K
Forward guidance
The company anticipates final PRIME database lock in mid-September and publication in time for key pregnancy and maternal health conferences in the spring. They are also executing cost-effective programs to educate patients and physicians on the PreTRM® Test and working to support the establishment of care guidelines.
Tailwinds
- Final PRIME database lock anticipated mid-September.
- PRIME publication in time for key pregnancy and maternal health conferences in the spring.
- Executing cost-effective programs to educate patients and physicians on the PreTRM® Test.
- Supporting the establishment of care guidelines.
- Conditional approval received from New York State on ambient whole-blood collection, allowing Sera to complete nationwide rollout of new blood collection method.
Headwinds
- Net losses and the potential need to raise more capital.
- Revenues from the PreTRM Test representing substantially all Company revenues to date.
- The need for broad scientific and market acceptance of the PreTRM Test.
- Potential third-party payer coverage and reimbursement.
- Changes in FDA regulation of laboratory-developed tests.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-1.9%
Avg return
Earnings day
-3.5%
Avg return
5 days after
-3.3%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+14.3%
Q3 2022
Best reaction
-11.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -8.0% | +18.1% | |
| Q4 2025 | -7.7% | +6.3% | +20.4% | |
| Q3 2025 | +1.7% | +8.5% | +19.0% | |
| Q1 2025 | -11.7% | -2.1% | -35.4% | |
| Q4 2024 | -5.1% | -2.2% | -17.9% | |
| Q3 2024 | -0.3% | -2.7% | -3.9% | |
| Q2 2024 | +0.0% | -1.2% | -2.2% | |
| Q1 2024 | +3.3% | -4.0% | -13.6% | |
| Q4 2023 | +3.4% | +1.1% | +7.7% | |
| Q3 2023 | -3.2% | -6.4% | +130.9% | |
| Q2 2023 | +0.8% | -10.1% | -39.9% | |
| Q1 2023 | -0.8% | -2.8% | -13.0% | |
| Q4 2022 | -10.0% | -9.5% | -22.3% | |
| Q3 2022 | +14.3% | +11.1% | -4.0% | |
| Q2 2022 | -4.1% | -6.3% | -27.3% | |
| Q1 2022 | -7.6% | -17.1% | -32.7% | |
| Q4 2021 | +3.6% | +0.3% | -39.3% | |
| Q3 2021 | +0.3% | -0.8% | -8.2% | |
| Q3 2020 | +0.3% | -0.8% | -8.2% | |
| Q2 2021 | -4.8% | -9.9% | +0.0% | |
| Q1 2021 | -4.8% | -9.9% | +0.0% | |
| Q4 2020 | -4.8% | -9.9% | +0.0% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro